MetaVia Inc. Reports Year-End 2025 Financial Results and Provides Corporate Update

Key Developments and Potential Share Price Catalysts

MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company specializing in cardiometabolic diseases, has released its financial and operational results for the year ended December 31, 2025, alongside a comprehensive corporate update. Several events detailed in this report have the potential to significantly impact shareholder value and influence the company’s share price.

1. Clinical Progress and Data Readouts

• DA-1726 Phase 1 Data: Positive results were announced from the extended 8-week, non-titrated 48 mg cohort of DA-1726, MetaVia’s lead asset. This novel dual oxyntomodulin (OXM) analog agonist—targeting both GLP1R and GCGR for obesity and related metabolic disorders—showed:
  • Robust early weight loss of 9.1%
  • Statistically significant reductions in waist circumference
  • Strong improvements in glucose control
  • Meaningful reductions in liver stiffness
  • Favorable safety and tolerability profile

  These results, achieved without titration, indicate DA-1726’s potential for a best-in-class profile in obesity and cardiometabolic disease.

• Upcoming Phase 1 Part 3 Study: IRB approval was received in March 2026 for a 16-week titration study evaluating higher doses (48 mg single-step, 64 mg two-step regimen) in obese adults. Dosing initiation is expected in April 2026, with data anticipated in Q4 2026. This timeline could be a significant catalyst for the stock, depending on study outcomes.
• Vanoglipel (DA-1241) Progress: Vanoglipel, a GPR119 agonist for MASH and potentially type 2 diabetes, showed positive Phase 2a data at AASLD The Liver Meeting 2025, with:
  • Clinically meaningful improvements in glucose control
  • Liver health improvement
  • Enhanced plasma lipidomic profiles over 16 weeks

  AI-modeling from Syntekabio confirmed strong inflammatory and cardiometabolic target engagement, further supporting its development.

2. Intellectual Property Strengthening

• DA-1726 IP Position: 39 granted and pending patents in the U.S. and internationally, providing protection through at least 2041. This robust IP estate could deter competition and enhance future commercial value.
• Vanoglipel IP Portfolio: 48 granted and pending patents across three families in major markets (U.S., Europe, Japan, China), providing protection until 2035 or longer if extended. Exclusive licensing from Dong-A ST Co., Ltd. covers compound, manufacturing, and broad therapeutic uses.

3. Financial Position and Capital Raise

• Cash Position: \$10.3 million in cash and equivalents at year-end 2025, down from \$16.0 million in 2024. With proceeds from a \$9.3 million public offering in January 2026, the company expects to fund operations into Q4 2026.
• Operating Expenses: Significant reduction in operating expenses:
  • R&D expenses: \$6.8 million in 2025, down from \$21.6 million in 2024
  • G&A expenses: \$6.9 million in 2025, down from \$7.3 million in 2024
  • Total operating expenses: \$13.7 million in 2025, down from \$28.8 million in 2024

  The decrease primarily reflects lower costs in vanoglipel and DA-1726 development, with modest increases in legal and employee costs.

• Net Loss: \$13.0 million (\$7.35 per share) in 2025, compared to \$27.6 million (\$39.13 per share) in 2024. The reduction is largely due to decreased R&D spending.
• Shares Outstanding: 1,766,026 weighted average shares in 2025, up from 705,193 in 2024 due to capital raises.

4. Operational and Scientific Milestones

• Phase 1 Part 3 DA-1726 Initiation (April 2026): This is a near-term event that may move the share price significantly depending on enrollment and preliminary data.
• Vanoglipel End-of-Phase Meeting with FDA: Scheduling in progress. Regulatory feedback could be pivotal for future development and valuation.
• AI-Driven Drug Discovery Collaboration with Syntekabio: Ongoing results reinforce vanoglipel’s potential for MASH and type 2 diabetes.

5. Shareholder Risks and Considerations

• Cash Sufficiency: Company states it is funded into Q4 2026, but further capital will likely be needed for late-stage trials or commercialization.
• Regulatory Timeline: Upcoming clinical and regulatory events are crucial. Delays or negative data could impact share price.
• Market and Patent Protection: Strong IP estates for both DA-1726 and vanoglipel provide competitive advantage, but expiration or litigation risks exist.
• Stock Volatility: Share count has increased, and warrant liabilities are affected by stock price volatility.

6. Summary for Investors

• MetaVia has made substantial progress in its clinical portfolio, most notably with DA-1726’s positive weight loss and metabolic data in Phase 1 and vanoglipel’s promising effects for MASH.
• Near-term catalysts include the initiation and data readout from new DA-1726 studies and regulatory progress for vanoglipel. These events could drive significant share price moves.
• The company’s cash position and reduced spending provide runway into late 2026, but future financings may be required.
• Strengthened intellectual property positions in both lead programs offer long-term value and differentiation.

Disclaimer

This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any securities. Forward-looking statements are subject to risks and uncertainties, and actual results may differ materially. Investors should review MetaVia’s filings with the SEC, including its most recent Annual Report on Form 10-K, for a full discussion of risks. Past performance is not indicative of future results.